ChEMBL ligand: CHEMBL682 (Amodiaquin, Amodiaquina, Amodiaquine, Amodiaquinum, GNF-Pf-5648, NSC-13453, SJ000110703, Sunoquine)
Amyloid-beta A4 protein in Human [ChEMBL: CHEMBL2487] [UniProtKB: P05067] There should be some charts here, you may need to enable JavaScript!
Hemozoin in Plasmodium falciparum [ChEMBL: CHEMBL613898] There should be some charts here, you may need to enable JavaScript!
Nuclear receptor related 1/Nuclear receptor subfamily 4 group A member 2 in Human [ChEMBL: CHEMBL5002] [GtoPdb: 630] [UniProtKB: P43354] There should be some charts here, you may need to enable JavaScript!
Plasmodium falciparum [ChEMBL: CHEMBL364] There should be some charts here, you may need to enable JavaScript!

DB	Assay description	Assay Type	Standard value	Standard parameter	Original value	Original units	Original parameter	Reference
Amyloid-beta A4 protein in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2487] [UniProtKB: P05067]
ChEMBL	Modulation of human wild-type APP695 expressed in SH-SY5Y cells assessed as inhibition of amyloid beta (1 to 42 residues) production measured after 24 hrs by ELISA	B	5.27	pIC50	5400	nM	IC50	Bioorg Med Chem (2018) 26: 2151-2164 [PMID:29559198]
ChEMBL	Modulation of human wild-type APP695 expressed in SH-SY5Y cells assessed as inhibition of amyloid beta (1 to 40 residues) production measured after 24 hrs	B	5.4	pIC50	4000	nM	IC50	Bioorg Med Chem (2018) 26: 2151-2164 [PMID:29559198]
Hemozoin in Plasmodium falciparum (target type: MACROMOLECULE) [ChEMBL: CHEMBL613898]
ChEMBL	Inhibition of beta-hematin	B	4.68	pIC50	21000	nM	IC50	J Med Chem (2016) 59: 6512-6530 [PMID:27299916]
ChEMBL	Inhibition of beta-hematin formation assessed as reduction in hemozoin formation incubated for 5 hrs by NP40 detergent-based assay	B	4.89	pIC50	13000	nM	IC50	Medchemcomm (2019) 10: 450-455 [PMID:31015908]
ChEMBL	Inhibition of Beta-hematin in Plasmodium falciparum NF54 assessed as hemozoin formation after 36 hrs by flow cytometry analysis	B	5	pIC50	10000	nM	IC50	J Med Chem (2022) 65: 16695-16715 [PMID:36507890]
ChEMBL	Inhibition of Beta-hematin assessed as bis-pyridyl-Fe(III)PPIX complex formation incubated for 5 hrs by NP40 detergent-mediated colorimetric assay	B	5.07	pIC50	8600	nM	IC50	J Med Chem (2021) 64: 2739-2761 [PMID:33620219]
Nuclear receptor related 1/Nuclear receptor subfamily 4 group A member 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5002] [GtoPdb: 630] [UniProtKB: P43354]
ChEMBL	Agonist activity at Gal4-fused human Nurr1 LBD expressed in HEK293T cells co-expressing firefly luciferase assessed as luciferase activity in presence of 5-(Pyridin-3-yl)-1-methylindole-3-carboxylic Acid Methyl Ester by hybrid reporter gene assay	B	4.09	pEC50	82000	nM	EC50	J Med Chem (2021) 64: 15126-15140 [PMID:34633810]
ChEMBL	Agonist activity at Gal4-fused human Nurr1 LBD expressed in HEK293T cells co-expressing firefly luciferase assessed as luciferase activity by hybrid reporter gene assay	B	4.39	pEC50	41000	nM	EC50	J Med Chem (2021) 64: 15126-15140 [PMID:34633810]
ChEMBL	Agonist activity at Gal4-fused human Nurr1 LBD expressed in HEK293T cells co-expressing firefly luciferase assessed as luciferase activity incubated for 12 to 14 hrs by hybrid reporter gene assay	B	4.44	pEC50	36000	nM	EC50	J Med Chem (2021) 64: 2659-2668 [PMID:33629841]
ChEMBL	Agonist activity at Gal4-fused human full length Nurr1 transfected in human HEK293T cells co-transfected with pFR-Luc/pRL-SV40 assessed as activation of luciferase activity incubated for 16 hrs by Dual-Glo luciferase assay	B	4.44	pEC50	36000	nM	EC50	J Med Chem (2023) 66: 13556-13567 [PMID:37751901]
ChEMBL	Agonist activity at Nurr1 ligand binding domain (unknown origin) measured by Gal4-based reporter gene assay	B	4.7	pEC50	20000	nM	EC50	J Med Chem (2022) 65: 9548-9563 [PMID:35797147]
Plasmodium falciparum (target type: ORGANISM) [ChEMBL: CHEMBL364]
ChEMBL	Antimalarial activity against Plasmodium falciparum 3D7 asexual forms incubated for 72 hrs by luminescence method	F	4.75	pIC50	17900	nM	IC50	Eur J Med Chem (2020) 188: 111983-111983 [PMID:31911292]
ChEMBL	Antiplasmodial activity against multidrug-resistant Plasmodium falciparum K1 infected in human erythrocytes after 48 hrs by [3H]-hypoxanthine incorporation assay	F	8.1	pIC50	8	nM	IC50	Bioorg Med Chem (2015) 23: 5419-5432 [PMID:26264839]
ChEMBL	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human A+ erythrocytes assessed as inhibition of [3H]-hypoxanthine incorporation after 42 hrs by beta counting method	F	8.22	pIC50	6	nM	IC50	Eur J Med Chem (2017) 126: 72-83 [PMID:27744189]
ChEMBL	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human A+ erythrocytes after 48 hrs by SYBR Green based fluorescence assay	F	8.22	pIC50	6	nM	IC50	Eur J Med Chem (2017) 126: 72-83 [PMID:27744189]
ChEMBL	Antimalarial activity against chloroquine-resistant and mefloquine-sensitive Plasmodium falciparum W2 ring stage form infected in human erythrocytes by spectrophotometric analysis	F	8.22	pIC50	6	nM	IC50	Bioorg Med Chem (2019) 27: 1002-1008 [PMID:30737133]
ChEMBL	Antiplasmodial activity against Plasmodium falciparum W2 infected in human erythrocytes after 48 hrs by [3H]-hypoxanthine incorporation assay	F	8.3	pIC50	5	nM	IC50	Bioorg Med Chem (2015) 23: 5419-5432 [PMID:26264839]
ChEMBL	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected in human erythrocytes after 48 hrs by [3H]-hypoxanthine incorporation assay	F	8.4	pIC50	4	nM	IC50	Bioorg Med Chem (2015) 23: 5419-5432 [PMID:26264839]
ChEMBL	Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 infected in human erythrocyte assessed as growth inhibition by SYBR Green-1 assay	F	7.91	pEC50	12.3	nM	EC50	Eur J Med Chem (2015) 102: 320-333 [PMID:26295174]
ChEMBL	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human erythrocyte assessed as growth inhibition by SYBR Green-1 assay	F	8.23	pEC50	5.85	nM	EC50	Eur J Med Chem (2015) 102: 320-333 [PMID:26295174]

ChEMBL data shown on this page come from version 35:

Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]